Format

Send to

Choose Destination
Eur J Pediatr Surg. 2014 Dec;24(6):461-6. doi: 10.1055/s-0034-1396420. Epub 2014 Dec 8.

Advances in fibrolamellar hepatocellular carcinoma: a review.

Author information

1
Department of Surgery, Pediatric Surgical Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States.

Abstract

Fibrolamellar hepatocellular carcinoma is a rare primary liver tumor that often arises in the absence of cirrhosis or viral hepatitis. Compared with hepatocellular carcinoma, patients are typically younger with less comorbidities. Diagnosis is often multimodal and requires a high level of suspicion, as traditional liver pathology markers, such as serum α fetoprotein and transaminases, are often normal. Overall, patients respond well to surgical resection but recurrences are frequent, and alternative therapies, such as chemotherapy and radiation, are not well studied. Currently, there are no established chemotherapy regimens; there are only limited case reports of select agents, such as 5-fluorouracil with interferon-α and gemcitabine with oxaliplatin, used with varying degrees of success. Because little is known about this rare tumor, the development of serum markers and alternative therapies continues to be a challenge. A major advancement in the understanding of this rare disease is the discovery of a functional chimeric transcript incorporating DNAJB1 and PRKACA. This finding may finally provide the basis for specific diagnostic markers and chemotherapies that patients with this disease have long needed. Here, we present advances in the surgical treatment of fibrolamellar hepatocellular carcinoma, as well as recent data on its tumor biology and pathogenesis.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01642186.

PMID:
25486412
DOI:
10.1055/s-0034-1396420
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center